Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Preferred Stock Liabilities (2017 - 2020)

Outlook Therapeutics (OTLK) has disclosed Preferred Stock Liabilities for 4 consecutive years, with $6.5 million as the latest value for Q1 2020.

  • On a quarterly basis, Preferred Stock Liabilities rose 28.34% to $6.5 million in Q1 2020 year-over-year; TTM through Mar 2020 was $6.5 million, a 28.34% increase, with the full-year FY2019 number at $5.4 million, up 13.2% from a year prior.
  • Preferred Stock Liabilities was $6.5 million for Q1 2020 at Outlook Therapeutics, down from $8.3 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $18.3 million in Q1 2018 to a low of $2.9 million in Q3 2017.
  • A 4-year average of $6.5 million and a median of $5.1 million in 2019 define the central range for Preferred Stock Liabilities.
  • Biggest YoY gain for Preferred Stock Liabilities was 69.91% in 2019; the steepest drop was 72.46% in 2019.
  • Outlook Therapeutics' Preferred Stock Liabilities stood at $2.9 million in 2017, then soared by 67.04% to $4.9 million in 2018, then skyrocketed by 69.91% to $8.3 million in 2019, then fell by 22.08% to $6.5 million in 2020.
  • Per Business Quant, the three most recent readings for OTLK's Preferred Stock Liabilities are $6.5 million (Q1 2020), $8.3 million (Q4 2019), and $5.4 million (Q3 2019).